Variables | OS (n = 110) | PFS (n = 107) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Original | Variables selected | Bootstrapc | Original | Variables selected | Bootstrapc | |||||
HR (95%CI) | P-valueb | HR (95%CI) | P-valueb | P-valueb | HR (95%CI) | P-valueb | HR (95%CI) | P-valueb | P-valueb | |
Histology | ||||||||||
Non-clear cell vs clear cell | 2.325 (1.293–4.181) | 0.005 | 2.108 (1.191–3.732) | 0.010 | 0.011 | 1.717 (1.008–2.926) | 0.047 | 1.606 (0.952–2.710) | 0.076 | 0.087 |
TNM stage at initial diagnosis | ||||||||||
IV vs I–III | 0.990 (0.565–1.736) | 0.972 | 0.988 (0.599–1.631) | 0.963 | ||||||
No. of metastatic sitesa | ||||||||||
≥ 2 vs 1 | 1.465 (0.867–2.477) | 0.154 | 1.946 (1.210–3.128) | 0.006 | 1.817 (1.138–2.902) | 0.012 | 0.026 | |||
Tyrosine kinase inhibitors | ||||||||||
Sorafenib vs Sunitinib | 1.431 (0.861–2.381) | 0.167 | 1.360 (0.858–2.154) | 0.191 | ||||||
Heng’s risk group | <0.001 | <0.001 | 0.005 | 0.036 | 0.011 | 0.035 | ||||
Favorable | reference | reference | reference | reference | ||||||
Intermediate | 1.955 (0.895–4.268) | 2.023 (0.964–4.244) | 1.212 (0.634–2.313) | 1.297 (0.701–2.398) | ||||||
Poor | 5.654 (2.267–14.103) | 6.760 (2.932–15.587) | 2.432 (1.095–5.398) | 2.771 (1.326–5.788) | ||||||
Tumoral CCR7 | ||||||||||
High vs Low | 2.242 (1.288–3.901) | 0.004 | 2.256 (1.336–3.809) | 0.002 | 0.003 | 1.782 (1.105–2.875) | 0.018 | 1.835 (1.156–2.912) | 0.010 | 0.013 |